[Diagnosis of energy metabolism in ENT tumors--a PET study].
The metabolism of malignant tumours can be determined in vivo by positron emission tomography. Fifty patients with malignant lesions of the head and neck were examined before therapy and followed up for 11-18 months. The course of the disease was related to the initial fluorodeoxyglucose (FDG) uptake of the tumour. There was a relation between FDG uptake and survival: an increased FDG uptake of more than 300-400% was related to a reduced survival rate. Patients with an uptake less than 300% had a much better prognosis.
Reisser
C
C
Hals-Nasen-Ohrenklinik, Universität Heidelberg.
Haberkorn
U
U
Strauss
L G
LG
D001786:Blood Glucose / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000378:metabolism; D004734:Energy Metabolism / Q000502:physiology*; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006393:Hemangiopericytoma / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010039:Otorhinolaryngologic Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D014055:Tomography, Emission-Computed
D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose
Stoffwechseldiagnostik bei HNO-Tumoren--eine PET-Studie.